Cannabidiol vs AMISULPRIDE
Leaving the study early ‐ medium term ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
The review found no eligible studies for this question.